NPCE has posted a strong recent earnings beat streak, but persistent cash burn, declining revenue, and failed momentum and asymmetry gates keep the quality-driven exit signal in force.
Thesis pillars
- Elevated Put Call Risk→Stable
- Cash Burning Weak Quality→Stable
- Declining Revenue Trend→Stable
- +2 more pillars — see the Why tab for full reasoning
Neuropace, Inc. (NPCE) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $16.99: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 2.17; Below-average business quality.
NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device for drug-resistant focal epilepsy, with more than 8,000 patients implanted as of December 31, 2025 targeting a U.S. population of about 575,000 eligible adults. The company generates... Read more
Sell if holding. Engine safety override at $16.99: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 2.17; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Score 3.9/10, high confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRNS System10-K Item 1A: 'We currently rely on our RNS System, which can only be marketed in the United States for use in adults with drug-resistant focal epilepsy, as our primary source of revenue.'
- HIGHSuppliersingle-source suppliers10-K Item 1A: 'We depend on a limited number of single-source suppliers and vendors in connection with the manufacture of our products, which makes us vulnerable to supply shortages and price fluctuations'
- MEDIUMCustomerDIXI Medical distribution agreement10-K Item 1A: 'With the expiration of our exclusive distribution agreement with DIXI Medical and loss of the associated revenue, our revenue growth, financial condition and results of operations may be'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Revenue shrinking — -2.0% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -21.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.99: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 2.17; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 67, MACD bullish. Prior stop was $16.12. Score 3.9/10, high confidence.
Take-profit target: $17.40 (+0.4% upside). Prior stop was $16.12. Stop-loss: $16.12.
Concentration risk — Product: RNS System; Concentration risk — Supplier: single-source suppliers; Target reached (0.4% upside).
Neuropace, Inc. trades at a P/E of N/A (forward -54.3). TrendMatrix value score: 5.6/10. Verdict: Sell.
14 analysts cover NPCE with a consensus score of 4.2/5. Average price target: $20.
What does Neuropace, Inc. do?NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device for drug-resistant focal...
NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device for drug-resistant focal epilepsy, with more than 8,000 patients implanted as of December 31, 2025 targeting a U.S. population of about 575,000 eligible adults. The company generates revenue from initial RNS System implants and recurring replacement-device sales as batteries reach end of service (average life of nearly 11 years), marketed through a direct U.S. sales force to roughly 200 Level 4 comprehensive epilepsy centers and an expanding base of community epileptologists and neurosurgeons.